Zavicefta plus Aztreonam Combination Therapy
For serious infections caused by metallo-β-lactamase (MBL)-producing carbapenem-resistant Enterobacterales (CRE), use ceftazidime-avibactam (Zavicefta) 2.5g IV every 8 hours combined with aztreonam 2g IV every 6-8 hours, administered simultaneously. This combination demonstrates significant mortality reduction (30-day mortality 19.2% vs 44% with other agents, HR 0.37) and lower clinical failure rates compared to alternative therapies 1.
Mechanism and Rationale
The combination exploits a critical vulnerability: aztreonam is not hydrolyzed by metallo-β-lactamases (NDM, VIM types), while avibactam protects aztreonam from other β-lactamases (including KPC and OXA-48) that the organism may co-produce 1. This dual protection creates synergistic activity specifically against MBL-producing organisms where ceftazidime-avibactam alone would fail.
Dosing Algorithm by Renal Function
Normal Renal Function (CrCl >90 mL/min)
- Ceftazidime-avibactam: 2.5g IV every 8 hours (infused over 2 hours)
- Aztreonam: 2g IV every 6-8 hours
- Administer simultaneously to maintain synchronized drug exposure 2
Moderate Renal Impairment (CrCl 31-90 mL/min)
- Ceftazidime-avibactam: Adjust per manufacturer guidance (dose reduction required)
- Aztreonam: 2g loading dose, then 1g every 8-12 hours
- Most regimens maintain ≥90% joint probability of target attainment 2
Severe Renal Impairment (CrCl 10-30 mL/min)
- Ceftazidime-avibactam: Further dose reduction per renal adjustment tables
- Aztreonam: 2g loading dose, then 500mg-1g every 12 hours (half the usual dose) 3
Hemodialysis
- Aztreonam: Give usual initial dose, then one-fourth maintenance dose at usual intervals, plus one-eighth initial dose after each dialysis session 3
- Coordinate ceftazidime-avibactam dosing post-dialysis
Critical Implementation Points
Identify carbapenemase type before initiating therapy whenever possible 1. This combination is specifically indicated for:
Do NOT use this combination for:
- KPC-producing CRE alone (use ceftazidime-avibactam monotherapy)
- OXA-48-producing CRE alone (use ceftazidime-avibactam monotherapy)
The 2023 guidelines provide a weak recommendation with very low-quality evidence, but emphasize that benefits likely outweigh harms 1. The 2022 ESCMID guidelines offer a conditional recommendation with moderate certainty specifically for severe infections caused by MBL-producing CRE resistant to newer monotherapies 5.
Clinical Outcomes Data
In prospective evaluation of bloodstream CRE infections caused by MBL-producers, the combination achieved:
- 63% reduction in 30-day mortality (HR 0.37,95% CI 0.13-0.74)
- 70% reduction in clinical treatment failure (HR 0.30,95% CI 0.14-0.65)
- 51% reduction in hospital length of stay (HR 0.49) 1
In mixed critical infections (71.9% critical cases, including intra-abdominal and hospital-acquired pneumonia), cure rates reached 77.5% for NDM or NDM+OXA-48 infections with overall mortality of 21% 1.
Synergy Testing Considerations
Not all isolates demonstrate synergy—testing is recommended when feasible 6, 7. Synergy rates vary by organism:
- Klebsiella pneumoniae: 91-97% across infection sites 6
- Escherichia coli: 67-93% depending on source 6
- Pseudomonas aeruginosa: Only 17-37% (poor candidate for this combination) 6
Recent data shows 62.5% overall synergy demonstration with significant MIC reduction when synergy present 8. Clinical improvement occurs more frequently with synergy-positive isolates (31.3% vs 12.5%), though microbiological clearance remains challenging 8.
Duration and Monitoring
Continue therapy for minimum 48 hours after clinical improvement or bacterial eradication evidence 3. Persistent infections may require several weeks of treatment 3.
Monitor for neurotoxicity risk: Ceftazidime trough concentrations >80 mg/L increase neurotoxicity risk, though this remains low across renal function strata with appropriate dosing 2.
Common Pitfalls
- Using this combination for non-MBL producers: Wastes aztreonam and increases resistance risk—use ceftazidime-avibactam alone for KPC/OXA-48
- Asynchronous administration: Separate infusion timing may create pharmacokinetic gaps in coverage—administer simultaneously 9
- Inadequate renal dose adjustment: Both agents require adjustment but at different thresholds—calculate creatinine clearance accurately 3, 2
- Assuming universal synergy: Particularly problematic with Pseudomonas aeruginosa where synergy rates are poor 6
The combination represents a pragmatic salvage option for MBL-producing CRE when newer agents (cefiderocol, aztreonam-avibactam) are unavailable, though logistical complexity of dual-agent administration requires careful coordination 9.